GLP-1 maintenance below BMI 30: what providers can actually offer

What did @louiseglp1educator actually say?

The short version: Louise claimed you can stay on a GLP-1 medication indefinitely as long as your BMI stays above 19, and restart after a break as long as your BMI is above 22. She framed this as a selling point for her provider, Voy, and included a referral code and instructions to photograph your pharmacy label to gain access. Her pitch was that dropping below a BMI of 30 does not have to mean stopping treatment.

She also promised "25% off, side effect management, clinical support and a personal coach" through Voy. The video is clearly affiliate-driven content. That context matters when evaluating what she's telling her 10,000-plus viewers about clinical eligibility thresholds.

Does the science back this up?

The claim that GLP-1 treatment can continue below a BMI of 30 is actually supported by evidence, but the specific BMI floors she cites (19 and 22) are not derived from clinical trial data. They appear to be Voy's internal eligibility rules, not medically established thresholds.

The landmark STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) enrolled participants with a BMI of 30 or above, or 27 or above with a weight-related comorbidity. That is the evidence base most prescribing guidelines are built on. The SELECT trial (Lincoff et al., 2023, NEJM) extended semaglutide use to patients with established cardiovascular disease and a BMI of 27 or above, regardless of diabetes status, strengthening the case for broader eligibility. Neither trial tested maintenance at BMIs as low as 19 or 22. A BMI of 19 sits at the lower boundary of what is considered a healthy weight. Prescribing a GLP-1 that suppresses appetite to someone at BMI 19 raises real clinical concerns that Louise does not acknowledge.

What did they get wrong (or right)?

Credit where it is due: the core premise, that GLP-1 eligibility does not automatically end when your BMI dips below 30, is legitimate. Guidelines from the American Gastroenterological Association and the Obesity Medicine Association have moved toward treating obesity as a chronic condition requiring long-term management, not a problem you fix and abandon. The framing that patients "fail" if they stop is consistent with what the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed: patients who discontinued tirzepatide regained significant weight within a year.

But Louise got some things wrong. Presenting a platform's commercial eligibility rules as if they were clinical standards is misleading. Saying you can stay on a GLP-1 "for absolutely as long as you need it" with no caveats about monitoring, bone density, muscle mass, or nutritional risk at low BMIs is irresponsible. And the instruction to photograph your pharmacy label to gain access to medication raises real questions about how Voy is verifying clinical history, which is a regulatory concern for any telehealth prescriber operating under state medical board oversight.

What should you actually know?

GLP-1 maintenance prescribing for patients below a BMI of 30 is not fringe medicine, but it should involve a real clinical assessment, not a referral code and a photo of a pill box. The Endocrine Society's 2024 clinical practice guidelines acknowledge individualized treatment beyond standard BMI cutoffs, but they also emphasize ongoing metabolic monitoring.

A BMI of 19 is not a safe floor for GLP-1 use in most people. The drugs reduce appetite significantly. Continuing them at that weight without close supervision risks undernutrition, sarcopenia, and other harms. No major clinical guideline endorses 19 as a minimum threshold. That number comes from Voy's terms, not from a peer-reviewed study.

If you are considering staying on a GLP-1 after hitting your weight goal, that conversation belongs with a licensed clinician who knows your full history, not with an affiliate marketer on TikTok.